Read by QxMD icon Read

Long acting atypical injections

Andreas Schreiner, Asaf Caspi, Paul Bergmans, Pierre Cherubin, Sofia Keim, Elsa Lara, Irina Pinchuk, Daniel Schuepbach, Sajid Suleman, Ludger Hargarter
RATIONALE: Long-acting injectable antipsychotic therapies may offer benefits over oral antipsychotics in patients with schizophrenia. OBJECTIVE: This study aimed to explore the safety, tolerability, and treatment response of paliperidone palmitate once-monthly in non-acute but symptomatic adult patients switched from previously unsuccessful monotherapy with frequently used oral atypical antipsychotics. METHODS: This was a post hoc analysis of a prospective, interventional, single-arm, international, multicenter, open-label, 6-month study...
January 2017: Psychopharmacology
Lisa A Raedler
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
Aislinn J Williams, Zhenni Wang, Stephan F Taylor
New-onset psychotic symptoms often respond well to antipsychotic treatment; however, symptoms may be difficult to treat when an underlying brain malformation is present. Here, we present a case of atypical psychotic symptoms in the context of a congenital cerebellar malformation (Dandy-Walker variant). The patient ultimately improved with paliperidone palmitate after multiple antipsychotic medication trials (both oral and one long-acting injectable) were ineffective. Neuroimaging may provide valuable diagnostic and prognostic information in cases of new-onset psychosis with atypical features and treatment resistance, even in the absence of neurologic signs and symptoms...
October 2016: Neurocase
Roberto Cadeddu, Dragana Jadzic, Ezio Carboni
Since the therapeutic treatment of depression is far from being satisfactory, new therapeutic strategies ought to be pursued. In addition, further investigation on brain areas involved in the action mechanism of antidepressants can shed light on the aetiology of depression. We have previously reported that typical and atypical antidepressants strongly stimulate catecholamine transmission in the bed nucleus of stria terminalis (BNST). In this study, we have built on that work to examine the effect of ketamine, an unusual antidepressant that can produce a fast-acting and long-lasting antidepressant effect after administration of a single sub-anaesthetic dose...
October 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Jun Ishigooka, Takamasa Noda, Kosuke Nishiyama, Noriko Tamaru, Tomoko Shima, Yumiko Yamasaki, Yoshihiro Tadori
Aripiprazole once-monthly (AOM) was previously approved for treatment of schizophrenia as monthly injections in the gluteal muscle. The deltoid muscle provides a more accessible injection site. The present study was conducted in Japanese schizophrenia patients as a 24-week, open-label trial that assessed the pharmacokinetics and safety of 5 sequential doses of AOM 400 mg (AOM 400) once every 4 weeks administered in the deltoid muscle. Patients treated with an oral atypical antipsychotic (other than aripiprazole) continued to receive their pre-study medication up to 14 days after the first AOM 400 injection...
June 2016: Nihon Shinkei Seishin Yakurigaku Zasshi, Japanese Journal of Psychopharmacology
Thomas R Einarson, Susana Maia-Lopes, Pushpendra Goswami, Basil G Bereza, Kristel Van Impe
OBJECTIVE: Patients with chronic schizophrenia suffer a huge burden, as do their families/caregivers. Treating schizophrenia is costly for health systems. The European Medicines Agency has approved paliperidone palmitate (PP-LAI; Xeplion), an atypical antipsychotic depot; however, its pharmacoeconomic profile in Portugal is unknown. A cost-effectiveness analysis was conducted from the viewpoint of the Portuguese National Health Service. METHODS: PP-LAI was compared with long acting injectables risperidone (RIS-LAI) and haloperidol (HAL-LAI) and oral drugs (olanzapine; oral-OLZ) adapting a 1-year decision tree to Portugal, guided by local experts...
September 2016: Journal of Medical Economics
Stephanie Sampson, Prakash Hosalli, Vivek A Furtado, John M Davis
BACKGROUND: Risperidone is the first new generation antipsychotic drug made available in a long-acting injection formulation. OBJECTIVES: To examine the effects of depot risperidone for treatment of schizophrenia or related psychoses in comparison with placebo, no treatment or other antipsychotic medication.To critically appraise and summarise current evidence on the resource use, cost and cost-effectiveness of risperidone (depot) for schizophrenia. SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Register (December 2002, 2012, and October 28, 2015)...
April 14, 2016: Cochrane Database of Systematic Reviews
Michael Langley-DeGroot, Yash Joshi, David Lehman, Sanjai Rao
No abstract text is available yet for this article.
June 2016: Journal of Clinical Psychopharmacology
Jasem Y Al-Hashel, Ismail Ibrahim Ismail, John K John, Mohammed Ibrahim, Mahmoud Ali
Myasthenia gravis is an autoimmune disease characterized by muscle weakness due to autoantibodies affecting the neuromuscular junction. Co-occurrence of myasthenia gravis and schizophrenia is very rare and raises a challenge in management of both diseases. Antipsychotic drugs exhibit anticholinergic side effects and have the potentials of worsening myasthenia. Long-acting risperidone is an injectable atypical antipsychotic drug that has not been previously reported to worsen myasthenia gravis in literature...
April 2016: Neuromuscular Disorders: NMD
Jean-Pierre Lindenmayer, Amandeep Kaur
Schizoaffective disorder (SAD) is an incapacitating illness that presents clinicians with challenges in terms of both its diagnosis and its psychopharmacological management. Most studies conducted on the psychopharmacological treatment of SAD also include patients with schizophrenia or other psychotic illnesses, thereby providing an unspecific view to the clinician as to the best way of treating patients with SAD. The objective of this article is to review studies on evidence-based treatment of patients with SAD...
April 2016: Drugs
C Khouri, S Planès, S Logerot, C Villier, M Mallaret
BACKGROUND: Neuroleptic malignant syndrome (NMS) is an uncommon but potentially fatal adverse effect of neuroleptic drugs. It is commonly characterized by muscular rigidity, fever, altered mental status, and autonomic dysfunction. Emerging of NMS is possible with all neuroleptics, classic and atypical. NMS occurs most often during the first week of treatment or after increasing the dosage of the neuroleptic medication. The frequency of NMS ranges from 0.07 to 2.2%. Its pathophysiology is not clearly understood but the blockade of dopamine receptors appears to be the central mechanism...
June 2016: L'Encéphale
LiLi Zhang, JiTao Li, YanJie Zhao, Yun'Ai Su, Tianmei Si
BACKGROUND: Paliperidone (9-hydroxyrisperidone), the major active metabolite of risperidone, has been introduced as a novel atypical antipsychotic agent in many countries. It is available both as an oral extended-release (ER) formulation and as a long-acting injection (paliperidone palmitate, PP), which have been approved for treating schizophrenia in the People's Republic of China since 2009 and 2012, respectively. This systematic review summarizes the efficacy, effectiveness, and safety of paliperidone in the treatment of schizophrenia in the Chinese population...
2016: Neuropsychiatric Disease and Treatment
Yongling Xiao, Erik Muser, Dong-Jing Fu, Marie-Hélène Lafeuille, Dominic Pilon, Bruno Emond, Allen Wu, Mei Sheng Duh, Patrick Lefebvre
BACKGROUND: Compared to oral atypical antipsychotics (OAAs), long-acting injectable antipsychotics require less frequent administration, and thus may improve adherence and reduce risk of relapse in schizoaffective disorder (SAD) patients. OBJECTIVE: To evaluate the impact of once monthly paliperidone palmitate (PP) versus OAAs on healthcare resource utilization, Medicaid spending, and hospital readmission among SAD patients. METHODS: Using FL, IA, KS, MS, MO, and NJ Medicaid data (January 2009-December 2013), adults with ≥2 SAD diagnoses initiated on PP or OAA (index date) were identified...
2016: Current Medical Research and Opinion
Michael Tempest, Christophe Sapin, Maud Beillat, Paul Robinson, Maarten Treur
BACKGROUND: Schizophrenia is a severe and debilitating psychiatric disorder. Pharmacological interventions aim to ameliorate symptoms and reduce the risk of relapse and costly hospitalisation. Despite the established efficacy of antipsychotic medication, compliance to treatment is poor, particularly with oral formulation. The emergence of long acting injectable (LAI) antipsychotic formulations in recent years has aimed to counteract the poor compliance rates observed and optimise long term patient outcomes...
December 2015: Journal of Mental Health Policy and Economics
Jacqueline A Pesa, Erik Muser, Leslie B Montejano, David M Smith, Oren I Meyers
BACKGROUND: Non-adherence to antipsychotic therapy among patients with schizophrenia is a key driver of relapse, which can lead to costly inpatient stays. Long-acting injectables (LAIs) may improve adherence, thus reducing hospitalizations, but inpatient cost reductions need to be balanced against higher drug acquisition costs of LAIs. Real-world evidence is needed to help quantify the economic value of oral atypical antipsychotics compared with LAIs. OBJECTIVE: The objective of this study was to compare healthcare costs and resource utilization between once-monthly paliperidone palmitate (PP) and oral antipsychotic therapy (OAT) in a population of Medicaid beneficiaries with schizophrenia...
2015: Drugs—Real World Outcomes
Marina Fàbrega, Gisela Sugranyes, Inmaculada Baeza
Paliperidone palmitate long-acting injection (PPLAI) is an atypical antipsychotic agent currently approved by the European Medicine Agency for the acute and maintenance treatment of schizophrenia in adults. However, there is no information so far on safety and effectiveness in patients under 18 years of age. We report on two clinical cases of adolescents with a psychotic spectrum disorder treated with PPLAI in an inpatient setting. The cases illustrate that PPLAI may hold potential as an effective and acceptably tolerated antipsychotic drug in adolescents with psychotic spectrum disorders...
October 2015: Therapeutic Advances in Psychopharmacology
Ana M Gaviria, José G Franco, Víctor Aguado, Guillem Rico, Javier Labad, Joan de Pablo, Elisabet Vilella
BACKGROUND: The analysis of prescribing patterns in entire catchment areas contributes to global mapping of the use of antipsychotics and may improve treatment outcomes. OBJECTIVE: To determine the pattern of long-term antipsychotic prescription in outpatients with schizophrenia in the province of Tarragona (Catalonia-Spain). METHODS: A naturalistic, observational, retrospective, non-interventional study based on the analysis of registries of computerized medical records from an anonymized database of 1,765 patients with schizophrenia treated between 2011 and 2013...
2015: PloS One
Thomas R Einarson, Hanna Pudas, Pushpendra Goswami, Kristel van Impe, Basil G Bereza
BACKGROUND: Atypical long-acting injectable (LAI) antipsychotics are increasingly available for treating chronic schizophrenia in patients chronically non-adherent to prescribed regimens. Few economic studies have compared these products. PURPOSE: To determine the cost-effectiveness of aripiprazole (ARI-LAI), paliperidone (PP-LAI), olanzapine (OLZ-LAI), and risperidone (RIS-LAI) in patients with chronic schizophrenia in Finland. METHODS: A 1-year decision tree model was adapted with guidance from an expert panel...
2016: Journal of Medical Economics
Alan I Green, Mary F Brunette, Ree Dawson, Peter Buckley, Amy E Wallace, Hisham Hafez, Marvin Herz, Meera Narasimhan, Douglas L Noordsy, Christopher O'Keefe, Roger W Sommi, Richard M Steinbook, Marjorie Weeks
OBJECTIVE: Alcohol use disorders worsen the course of schizophrenia. Although the atypical antipsychotic clozapine appears to decrease alcohol use in schizophrenia, risperidone does not. We have proposed that risperidone's relatively potent dopamine D2 receptor blockade may partly underlie its lack of effect on alcohol use. Since long-acting injectable (LAI) risperidone both results in lower average steady-state plasma concentrations than oral risperidone (with lower D2 receptor occupancy) and encourages adherence, it may be more likely to decrease heavy alcohol use (days per week of drinking 5 or more drinks per day) than oral risperidone...
October 2015: Journal of Clinical Psychiatry
Jun Soo Kwon, Sung Nyun Kim, Jaewook Han, Sang Ick Lee, Jae Seung Chang, Jung-Seok Choi, Heon-Jeong Lee, Seong Jin Cho, Tae-Youn Jun, Seung-Hwan Lee, Changsu Han, Kyoung-Uk Lee, Kyung Kyu Lee, EunJung Lee
Patient satisfaction with treatment is an important clinical index associated with the efficacy and adherence of treatment in schizophrenia. Although switching from oral antipsychotics to the long-acting injectable formulation may improve convenience, patient satisfaction has not been studied extensively. We carried out a 21-week, multicenter, randomized, open-label comparative study. A total of 154 patients with schizophrenia unsatisfied with current oral atypical antipsychotics were assigned randomly to either immediate or delayed switching to paliperidone palmitate, the long-acting injectable formulation of paliperidone...
November 2015: International Clinical Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"